Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.62 |
| ▸ | DRD2 | P14416 | 7/20 | 0.60 |
| ▸ | DRD3 | P35462 | 7/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018254 | 0.88 | KDM4E (0.62) | DRD2DRD3KDM4EALDH1A1GAA | |
| SCHEMBL24076389 | 0.84 | SLC6A2 (0.64) | DRD2DRD3HTR1AHTR2AKDM4E | |
| SCHEMBL30301379 | 0.84 | SLC6A2 (0.64) | DRD2DRD3HTR1AHTR2AKDM4E | |
| SCHEMBL24614079 | 0.84 | DRD2 (0.54) | DRD2DRD3HTR1AHTR2AKDM4E | |
| SCHEMBL76132 | 0.83 | MLLT1 (0.69) | KDM4EALDH1A1GAAMAPK1SLC2A1 | |
| SCHEMBL75198 | 0.83 | MLLT1 (0.65) | DRD2DRD3KDM4EALDH1A1GAA | |
| SCHEMBL24614046 | 0.82 | KDM4E (0.65) | AKR1C3DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL19850663 | 0.82 | NPC1 (0.56) | DRD2DRD3KDM4EALDH1A1GAA | |
| SCHEMBL21490113 | 0.82 | SMYD3 (0.71) | KDM4EALDH1A1GAAMAPK1SLC2A1 | |
| SCHEMBL19710676 | 0.82 | SMYD3 (0.71) | KDM4EALDH1A1GAAMAPK1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | DRD3, ADRB3, VDR | AKR1C3 630/4885DRD2 7/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.